

Mr. Corey Lian
Adviser, Listings Compliance (Sydney)
Australian Securities Exchange

20 October 2020

By email

Price Query

Dear Corey

We refer to the ASX Price Query letter dated 20 October 2020 and respond as follows:

1. The Company is not aware of any information concerning it that would, if known by some in the market, explain the recent trading in its securities. On 8 October 2020 the Company announced the dosing of the first subjects in its Phase 1 clinical trial of AMP945, the Company's experimental Focal Adhesion Kinase inhibitor, which is being developed for difficult to treat cancers and fibrotic diseases. There have been no material developments of any description since that date.
2. Not Applicable.
3. The Company is not able to offer any explanation for the recent trading in its securities. The Company notes that recent press coverage may have contributed to raising the profile of the Company in the marketplace.
4. The Company believes that it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
5. This response has been authorised and approved by the Company's Managing Director and CEO who has been delegated authority from the Board to respond to the ASX on disclosure matters.

Please do not hesitate to contact me if you require any additional information in relation to this matter.

Yours sincerely



Andrew J. Cooke
Company Secretary

About the Phase 1 Trial

The trial is a conventional randomised, placebo-controlled clinical trial which is designed to evaluate the safety and tolerability profile of AMP945 in healthy volunteers. Pharmacokinetics, or how AMP945 is absorbed and excreted by humans, will also be assessed. Additionally, some subjects in the trial will have samples tested to compare the drug levels in blood with the degree of FAK inhibition.

The trial will enrol up to 64 volunteers and is divided into three parts. In Part A, volunteers will be given single ascending single oral doses of AMP945 or placebo. In Part B, the effect of food on the oral absorption of AMP945 will be assessed and in Part C, volunteers will be given multiple ascending oral doses of AMP945 or placebo. The Company expects to complete dosing in the trial during the first half of next year, which should allow reporting of top-line results around the middle of 2021. Subject to the results of the Phase 1 trial, the Company plans to progress AMP945 into Phase 2 clinical testing in patients towards the end of 2021.

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company (ASX:ATX) advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer therapy and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF).

For Further Information

Dr. John Lambert

Chief Executive Officer

john@ampliatx.com

www.ampliatx.com



20 October 2020

Reference: 26282

Mr Andrew Cooke
Company Secretary
Amplia Therapeutics Limited

By email:

Dear Mr Cooke

Amplia Therapeutics Limited ('ATX'): Price - Query

ASX refers to the following:

- A. The change in the price of ATX's securities from a low of \$0.29 to a high of \$0.355 today.
- B. The significant increase in the volume of ATX's securities traded from 19 October 2020 to 20 October 2020.

Request for information

In light of this, ASX asks ATX to respond separately to each of the following questions and requests for information:

1. Is ATX aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
 - (a) Is ATX relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in ATX's securities would suggest to ASX that such information may have ceased to be confidential and therefore ATX may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that ATX may have for the recent trading in its securities?
4. Please confirm that ATX is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that ATX's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of ATX with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **3:00 PM AEDT Tuesday, 20 October 2020**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, ATX's obligation is to disclose the information

'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require ATX to request a trading halt immediately.

Your response should be sent to me by e-mail at ListingsComplianceSydney@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in ATX's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in ATX's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to ATX's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that ATX's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

We reserve the right to release a copy of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Questions

If you have any questions in relation to the above, please do not hesitate to contact me.

Kind regards

Corey Lian
Listings Adviser, Listings Compliance (Sydney)